Patients’, clinicians’ and research’s priorities on important outcomes in multiple myeloma: A mixed-methods study.
This study examined how outcome priorities differ among patients with multiple myeloma, clinicians, and randomized contr...
Immunoglobulin supplementation and longer dosing intervals reduce risk of infections in patients with RRMM treated with teclistamab.
- Post category:Hematologic Cancers
- Reading time:1 min read
Study type and population - Single-center retrospective cohort of 80 patients with relapsed/refractory multiple myelom...
Validation of the 2025 IMS/IMWG risk classification in patients with newly diagnosed multiple myeloma treated with quadruplets and autologous stem cell transplant.
- Post category:Hematologic Cancers
- Reading time:2 mins read
Study focus The authors evaluated whether recently proposed 2025 International Myeloma Society/International Myeloma W...
Two Drugs, One Stunning Myeloma Result.
- Post category:Hematologic Cancers
- Reading time:1 min read
This report describes a clinical study in relapsed multiple myeloma where a BCMA-directed T‑cell engager was combined...
In Vivo CAR T Cells Deliver Deep Responses in Myeloma.
- Post category:Hematologic Cancers
- Reading time:1 min read
This report describes early clinical results of an in vivo CAR T-cell approach for relapsed multiple myeloma, in which p...
Impact of body mass index on the prognosis of patients with newly diagnosed multiple myeloma.
- Post category:Hematologic Cancers
- Reading time:1 min read
This study assessed how body mass index (BMI) at diagnosis affects outcomes in 834 patients with newly diagnosed multipl...